COST-EFFECTIVENESS CLAIMS SHOULD NOT BE BASED ONLY ON COMPARISON OF DRUG ACQUISITION COSTS, FDA's DDMAC AND ANTI- INFECTIVE GROUPS WRITE TO INDUSTRY
Executive Summary
Drug acquisition costs should not be the sole basis for cost- effectiveness claims for anti-infectives, an FDA guidance letter to all holders of applications for antibiotic/anti-infective products states.